Business Wire

Aquanima Grupo Santander Wins Prestigious El Diamante de la Compra 2022 Award for Procurement Innovation Through its Partnership with Globality

Share

Aquanima Grupo Santander, a global procurement company that provides value solutions to Santander Group and other clients from different sectors around the world, has won the renowned AERCE El Diamante de la Compra® Award in the Innovation category for the way Santander is using Globality’s AI-powered Platform and Marketplace to transform how the bank sources B2B services.

The AERCE El Diamante de la Compra® Awards – organized by the Spanish Association of Purchasing, Contracting and Procurement Professionals (AERCE) – recognize outstanding work from procurement teams, and highlight the increasingly important function they play within their organizations, showcasing best practices and strategically valuable projects over the past 12 months.

The Innovation category recognizes a project, action or initiative that has demonstrated true innovation. The award is given to the procurement team that can demonstrate a radical new method or approach to one of the most challenging aspects of the sourcing process.

As a result of the partnership with Globality, Aquanima Grupo Santander is enjoying improved demand management and increased sourcing competition, and able to make more effective decisions, realize significant time and cost efficiencies, and foster greater collaboration between business stakeholders, procurement, and suppliers.

“We are delighted to receive this award, which is testament to our shared vision for the Future of Procurement,” said Jorge de la Vega, CEO of Aquanima. “That future, based on self-serve sourcing, is a competitive advantage for Aquanima Grupo Santander, helping us to continually evolve and boost our capabilities to give the best service to our clients.”

Aquanima’s project realized significant results within 90 days of adopting Globality’s Platform. In particular, Santander Bank realized substantial efficiencies by scoping their requirements in days instead of weeks, and awarding work in less than a month, drastically increasing speed to market and also saw average cost savings of 15% across projects awarded on the Platform.

“Globality is proud to partner with Aquanima Grupo Santander in revolutionizing the way Fortune 500 and Global 2000 companies buy services,” said Joel Hyatt, Chairman, Co-Founder and CEO, Globality. “For the first time, sophisticated, AI-powered technology exists to enable fair, competitive, sustainable self-serve sourcing for all indirect spend – unlocking a huge, new opportunity for procurement to create strategic business value and help meet the challenges of today’s volatile global economy.”

About Aquanima Grupo Santander

Aquanima Grupo Santander is a global procurement company with more than 20 years of experience that provides value solutions to Grupo Santander and other clients from different sectors around the world. Aquanima manages +10 billion per year, carries out more than 10,000 operations and homologates more than 5,000 suppliers.

Its expertise has been key for Grupo Santander to obtain the best efficiency ratio in the European financial industry. A knowledge that the company applies to the market in the 13 countries it’s placed, to +100 clients, thanks to the best team of +500 procurement experts.

Aquanima’s offer includes global solutions, both strategic and tactical that the company operates locally being adapted to each client needs in the sector and region in which they are located. All its solutions are applied under ESG criteria through its own TPRM model.

About Globality

Globality is a Silicon Valley-headquartered technology company co-founded by Joel Hyatt and Lior Delgo to connect global companies with the best suppliers at the right price for any sourcing need across every service category. Through its AI-powered Platform and Smart Sourcing technologies, Globality is bringing digital transformation to the sourcing industry. Globality’s AI digital solution replaces the archaic analog Request for Proposal, efficiently and effectively scoping needs, managing demand, matching companies with outstanding suppliers that meet their specific service needs, and cutting the sourcing process from months to hours while delivering savings of 20% or more. In January 2021, Globality raised $138 million from Sienna Capital and the SoftBank Vision Fund, bringing the total investment it has raised since its founding six years ago to $310 million. For more information, visit www.globality.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aquanima
Noelia Tapia
noelia.tapia@aquanima.com

Nardi Media for Globality (US)
Ashley Bernardi
ashley@nardimedia.com

Missive for Globality (UK)
James Gullis
james.gullis@missive.co.uk

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting26.5.2022 12:00:00 CEST | Press release

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June 9-17; virtual and in Vienna). “We are committed to advancing science that can lead to solutions for patients with serious unmet medical needs, including those with cancer,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “For that reason, we look forward to convening with the oncology community and presenting data from across our portfolio, including both Incyte-led and partnered programs.” Key abstracts accepted by EHA include: Oral Presentation Long-term Efficacy and Safety Results from an Ongoing Open-Label Phase 2 Study of Parsaclisib for the Treatment of Autoimmune Hemolytic Anemia (AIHA) (Abstract #S286. Session: Transfusion and Autoimmune Hemolytic Anemia. Session Time: Friday, June 10, 11:30 a.m. - 12:45 p.m.) Poster Presentations A Real-World Evaluation of the Association

H.I.G. Capital Expands Its Capital Formation Middle East Team with the Addition of Oliver Slade26.5.2022 12:00:00 CEST | Press release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with over $49 billion of capital under management, is pleased to announce that Oliver Slade has joined the firm’s Capital Formation Group, as a Managing Director, based in Dubai. Oliver will be responsible for capital raising and investor relations activities in the Middle East. He has been based in the region since 2008 and has over 17 years of experience in alternative assets. Oliver joins H.I.G. from Partners Group, where he was the Head of Middle East and Africa, responsible for the development and capital raising activities across private markets funds and solutions in the region. Prior to Partners Group, Oliver held a similar role at GAM investments. Jordan Peer Griffin, Executive Managing Director and Global Head of Capital Formation, commented: “We are delighted to welcome Oliver to H.I.G. Given his experiences in the region, Oliver is a key addition to establish a local presence in the Middle East, wh

500 Billion Gallons of Water Prevented from Flooding Communities in 2021, Using Xylem Technology26.5.2022 12:00:00 CEST | Press release

Solutions from global water technology company Xylem (NYSE:XYL), helped prevent more than 500 billion gallons of polluted water from flooding communities in 2021, according to its annual Sustainability Report. The report highlights the Company’s work with customers and partners to solve the world’s greatest water challenges. It also details Xylem’s progress to reduce its operational footprint, including cutting Scope 1 and 2 greenhouse gas (GHG) emission intensity by 12 percent and water use by 22 percent, versus 2019. “It’s a great privilege to have a leading portfolio of technologies and services to help our customers and communities solve the water challenges so central to a more sustainable world,” said Patrick Decker, president and CEO of Xylem. “We have a responsibility to make a difference, working alongside our customers and partners, and the communities we all serve. That’s why our sustainability report is more than a set of numbers. It’s a report card on the difference we’re

SCREEN Increases Efforts to Reduce the Environmental Impact of the Semiconductor Industry26.5.2022 10:43:00 CEST | Press release

SCREEN Semiconductor Solutions Co., Ltd. (SCREEN SPE), a subsidiary of SCREEN Holdings Co., Ltd., has announced it will increase its efforts to reduce the company’s environmental overall impact. The SCREEN Group is committed to both achieving a sustainable global society and to improving its sustainable value (social value) and has formulated a medium-term management plan titled Sustainable Value 2023 targeting these goals. The plan identifies specific issues in each of the environmental, social, and governance (ESG) fields. Concerning the environment, SCREEN is working to provide products and services that actively contribute to the reduction of ecological burden. Its efforts include improving the environmental performance of its products, reducing the effects of its business activities on climate change, promoting effective utilization of water resources, increasing recycling of products and parts, and helping to preserve biodiversity. Concretely, SCREEN SPE seeks to reduce the impac

CARVYKTI ® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:10:00 CEST | Press release

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel in December 2017. CARVYKTI® is a chimeric antigen receptor T-cell (CAR-T) therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies.1 CAR-T therapy is specifically developed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom